Bradford T. Whitmore

This profile gathers the share dealings of Bradford T. Whitmore across 3 companies, led by Ultralife Corp, Solesence, Inc. and Clearside Biomedical, Inc. In total, 40 filings cover trades dated from 10 February 2016 to 12 March 2026.

On the open market, the record shows 36 purchases worth €13.7M and 2 sales worth €29.3M. The totals exclude 1 filing filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. 2026 to date brings 1 purchase and no sales.

In size, the median ticket on the buying side is €59k. As a share of market capitalisation, the median purchase stands at 0.094%, based on 3 purchases. On 23 out of 35 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

On 16 March 2026 came the latest disclosure, an open-market purchase for €174k in Ultralife Corp. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.